Perspectives
Biosimilar Pipeline Quarterly Update: March 2023
Critical updates in an ever-changing environment
March 27, 2023This quarterly pipeline wrap-up provides a review of newly approved biosimilars, an update on the biosimilar pipeline and news of note on biosimilars in the approval process. See separate articles for updates on traditionaldrugs, specialty drugs and cell/gene therapies.
New Drug Information
- None
New Indications
- None
Biosimilar Product Approvals in the Past Twelve Months
| Generic Name | Brand Name | Reference
Product |
Manufacturer | Indication(s) | Route of Administration | Month Approved |
| adalimumab-aacf | Idacio® | Humira® | Fresenius | Autoimmune | SC | December 2022 |
| insulin glargine-aglr
Interchangeable biosimilar |
Rezvoglar® | Lantus® | Eli Lilly | Diabetes | SC | November 2022 |
| bevacizumab-adcd | Vegzelma® | Avastin® | Celltrion | Oncology | IV | September 2022 |
| pegfilgrastim-fpgk | Stimufend® | Neulasta® | Fresenius Kabi | Neutropenia | IV or SC | September 2022 |
| adalimumab-bwwd 100mg/mL | Hadlima® HC | Humira® | Samsung Bioepis/ Organon | Autoimmune | SC | August 2022 |
| ranibizumab-eqrn
Interchangeable biosimilar |
Cimerli® | Lucentis® | Coheres biosciences/bioeq | Age-related macular degeneration | Injection into the eye | August 2022 |
| pegfilgrastim-pbbk | Fylnetra™ | Neulasta® | Amneal/ Kashiv (Adello) | Neutropenia | IV or SC | May 2022 |
| bevacizumab-maly | Alymsys™ | Avastin® | mAbxience/ Insud Pharma/ Amneal | Oncology | IV | April 2022 |
Biosimilar Pipeline
| Generic Name | Brand Name | Manufacturer | Indication(s) | Route of Administration | Anticipated Approval date* |
| Oncology | |||||
| SB8 (bevacizumab biosimilar) | N/A (Avastin® biosimilar) | Samsung Bioepis/ Merck | Oncology | IV | 2023 |
| FKB238 (bevacizumab biosimilar) | N/A (Avastin® biosimilar) | Centus Biotherapeutics | Oncology | IV | 2023 |
| BAT-1706 (bevacizumab biosimilar) | N/A (Avastin® biosimilar) | Bio-thera solutions | Oncology | IV | 2023 |
| HLX02 (trastuzumab biosimilar) | N/A (Herceptin® biosimilar) | AccordBioPharma (Intas)/ Shanghai Henlius Biotech | Oncology | IV | 2023 |
| Blood Modifiers | |||||
| pegfilgrastim | Lupifil-p® (Neulasta® biosimilar) | Lupin | Neutropenia | SC | 2023 |
| pegfilgrastim | Lapelga® (Neulasta® biosimilar) | Apotex/Accord | Neutropenia | SC | 2023 |
| TX01 (filgrastim biosimilar) | N/A (Neupogen® biosimilar) | Tanvex BioPharma | Neutropenia | SC | 2023 |
| filgrastim | Grastofil® (Neupogen® biosimilar) | Apotex/Accord | Neutropenia | SC | 2023 |
| Ophthalmology | |||||
| ranibizumab | Xlucane® (Lucentis® biosimilar) | Xbrane & Bausch | Age-related macular degeneration | Injection into the eye | 2023 |
| MYL1701P (aflibercept) | N/A (Eylea® biosimilar) | Mylan | Age-related macular degeneration | Injection into the eye | 2023 |
| Autoimmune | |||||
| CTP17 (adalimumab) | Yuflyma® (Humira® biosimilar) | Celltrion | Autoimmune | SC | 2023 |
| MSB11456 (tocilizumab) | N/A (Actemra® IV/SC biosimilar) | Fresenius | Autoimmune | IV/SC | 2Q2023 |
| BIIB800 (tocilizumab) | N/A (Actemra® IV/SC biosimilar) | Biogen | Autoimmune | IV/SC | 10/2023 |
| ABP654
(ustekinumab) |
N/A (Stelara® SC biosimilar) | Amgen | Autoimmune | SC | 2H2023 |
| AVT04
(ustekinumab) |
N/A (Stelara® SC biosimilar) | Alvogen/Alvotech | Autoimmune | SC | 2H2023 |
| Immunosuppressant | |||||
| PB006 (natalizumab) | N/A (Tysabri® biosimilar) | Sandoz-Polpharma | Multiple sclerosis | IV | 5/2023 |
| Bone Health | |||||
| GP2411 (denosumab) | N/A (Prolia® biosimilar) | Sandoz | Osteoporosis | SC | 12/2023 |
Related news
Perspectives
May 1, 2024
Prime Therapeutics releases new clinical insights report, “Weight management: A holistic journey”
Report encourages providers to consider health contexts and lifestyle modifications as well as personal preferences and current guidelines when prescribing GLP-1s for weight loss
Perspectives
April 30, 2024
AMCP 2024: Behind the GLP-1 Spotlight Session with Ben Urick
Urick, senior principal health outcomes researcher, shares more about his Spotlight Session at the Academy of Managed Care Pharmacy (AMCP)’s Annual Meeting
Perspectives
April 30, 2024
Quarterly Drug Pipeline
Clinical insights and competitive intelligence on anticipated drugs in development